{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T17:00:41Z","timestamp":1759683641563,"version":"3.37.0"},"reference-count":61,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction Biology"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Opioid receptor antagonism has been shown to attenuate behavioral and neurochemical effects of amphetamine in humans and rodents. The effects of acute (oral or subcutaneous) or extended\u2010release naltrexone (XR\u2010NTX) were tested on the reward\u2010enhancing effects of amphetamine using the intracranial self\u2010stimulation (ICSS) paradigm. Acute exposure to drugs of abuse reduces the locus of rise (LOR) in the ICSS procedure, reflecting enhanced brain stimulation reward (BSR). Rats were treated once a day with naltrexone orally (PO; 5.0\u2003mg\/kg) or subcutaneously (SC; 0.5\u2003mg\/kg) for four consecutive days and tested with D\u2010amphetamine (0.5\u2003mg\/kg, intraperitoneal) in the ICSS paradigm 30 minutes later on days 1 and 4. Separate groups of rats received XR\u2010NTX (50\u2003mg\/kg, SC) or placebo microspheres (similar mass to XR\u2010NTX, SC) on day 0 and tested with D\u2010amphetamine in the ICSS paradigm on days 4, 14, 21, 28 and 41 after administration. Naltrexone plasma concentrations were determined for each amphetamine testing session using liquid chromatography\u2010mass spectrometry\/mass spectrometry (LC\u2010MS\/MS). In rats pretreated with naltrexone acutely, amphetamine\u2010potentiated BSR did not differ from vehicle\u2010pretreated rats on either day 1 or day 4 (25\u201330% decrease in LOR). In XR\u2010NTX\u2010pretreated rats, amphetamine\u2010potentiated BSR was reduced by 64 and 70% on days 4 and 14, respectively, compared to placebo microsphere\u2010treated controls. This effect dissipated by day 21. Naltrexone plasma concentrations were comparable across all treatment groups (14\u201330\u2003ng\/ml) on days 1, 4 and 14. In summary, an extended\u2010release formulation of naltrexone results in significant attenuation of psychostimulant\u2010enhanced BSR that is not observed with acute naltrexone.<\/jats:p>","DOI":"10.1111\/j.1369-1600.2009.00161.x","type":"journal-article","created":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T10:18:50Z","timestamp":1243851530000},"page":"408-418","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["PRECLINICAL STUDY: Route of administration affects the ability of naltrexone to reduce amphetamine\u2010potentiated brain stimulation reward in rats"],"prefix":"10.1111","volume":"14","author":[{"given":"Mark S.","family":"Todtenkopf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal S.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Kriksciukaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan Z.","family":"Turncliff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reginald L.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Ostrovsky\u2010Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Deaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(94)90074-4"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050288"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300811"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300274"},{"key":"e_1_2_7_6_1","first-page":"119","article-title":"Naltrexone, naloxone, and nalmefene have mixed agonist\/antagonist properties at the kappa opioid receptor","volume":"33","author":"Bidlack JM","year":"2007","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2252-05.2005"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01171.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2005.05.028"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0722397.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06995"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1037\/0735-7044.101.2.209"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2741\/1559"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2008.02.006"},{"key":"e_1_2_7_15_1","first-page":"814","article-title":"Route of administration affects the ability of naltrexone to reduce alcohol consumption in rats","volume":"33","author":"Dean RL","year":"2007","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.14.5274"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(96)00344-9"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-45734-8_3"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2005.01.032"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0022-3565(25)27077-X","article-title":"Effect of drugs on the uptake, release, and metabolism of h3\u2010norepinephrine in the rat Brain","volume":"149","author":"Glowinski J","year":"1965","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0731066.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2008.08.021"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90228-F"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1139\/y98-017"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2001.85.3.1153"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1152\/jn.01115.2002"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.17.030194.000335"},{"key":"e_1_2_7_28_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-3565(25)29807-X","article-title":"Behavioral effects of separate and combined administration of naloxone and d\u2010amphetamine","volume":"189","author":"Holtzman SG","year":"1974","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(92)90027-D"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301572"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/08039480510023052"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000144893.29987.e5"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-3565(25)10806-9","article-title":"Interaction between opioid antagonists and amphetamine: evidence for mediation by central delta opioid receptors","volume":"262","author":"Jones DN","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199707)26:3<269::AID-SYN8>3.0.CO;2-5"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305796200"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.25.112701.142758"},{"volume-title":"Guide for the Care and Use of Laboratory Animals","year":"1996","author":"National Research Council","key":"e_1_2_7_37_1"},{"volume-title":"NSDUH Series H\u201032, DHHS Publication no SMA 07\u20104293","year":"2007","author":"Office of Applied Studies","key":"e_1_2_7_38_1"},{"volume-title":"The Rat Brain in Stereotaxic Coordinates","year":"2005","author":"Paxinos G","key":"e_1_2_7_39_1"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj070361"},{"key":"e_1_2_7_41_1","first-page":"160","volume-title":"Annals of the New York Academy of Sciences","author":"Sato M","year":"1992"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130051016"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03558.x"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.4.1544"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1990.tb04963.x"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)94124-G"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)91400-5"},{"key":"e_1_2_7_48_1","first-page":"15","volume-title":"Neuropharmacological Basis of Reward","author":"Stellar JR","year":"1989"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470259818.ch12"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1680-y"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3070-06.2006"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.05.029"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(89)90444-9"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244190"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(01)00178-4"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.010"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1105-1429"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)01422-E"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02180030"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00063-5"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(82)90076-4"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301463"}],"container-title":["Addiction Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1369-1600.2009.00161.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1369-1600.2009.00161.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T21:13:32Z","timestamp":1739135612000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1369-1600.2009.00161.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,8]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1369-1600.2009.00161.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1369-1600.2009.00161.x","archive":["Portico"],"relation":{},"ISSN":["1355-6215","1369-1600"],"issn-type":[{"type":"print","value":"1355-6215"},{"type":"electronic","value":"1369-1600"}],"subject":[],"published":{"date-parts":[[2009,9,8]]},"assertion":[{"value":"2009-09-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}